{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:22:17Z","timestamp":1757701337904,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past four decades. We describe a Chinese man with this rare condition and explored the postulated mechanisms that may explain this phenomenon. We compiled similar cases that were previously reported and compared their etiology, progress, and response to treatment. On the basis of these cases, we derived a list of differential diagnoses to consider in patients with secondary resistance to dopamine agonists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 63-year-old Chinese man presented with blurred vision and was subsequently diagnosed with a macroprolactinoma. He had initial response to cabergoline but developed secondary resistance to it after 5\u00a0years. The prolactinoma continued to grow, and his serum prolactin remained markedly elevated despite adherence to escalating dosages of cabergoline up to 6\u00a0mg\/week. The patient finally underwent transsphenoidal surgery and was found to have a sparsely granulated lactotroph tumor with Ki-67 index of 5%. Postoperatively, there was improvement in his serum prolactin level, although he still required treatment with cabergoline at 6\u00a0mg\/week.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Surgery can facilitate disease control in patients with prolactinomas that develop secondary resistance to dopamine agonists. Malignant prolactinoma is an important differential diagnosis in this group of patients, especially when serum prolactin remains markedly elevated despite resolution or stability of the primary pituitary lesion, suggesting a metastatic source of prolactin secretion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03820-5","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:46:14Z","timestamp":1679863574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Macroprolactinoma with secondary resistance to dopamine agonists: a\u00a0case report and review of the literature\u00a0"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-6238","authenticated-orcid":false,"given":"Eng-Loon","family":"Tng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-0409","authenticated-orcid":false,"given":"Ada Ee Der","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aye Thida","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"issue":"3","key":"3820_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/beem.1999.0036","volume":"13","author":"RN Clayton","year":"1999","unstructured":"Clayton RN. Sporadic pituitary tumours: from epidemiology to use of databases. Baillieres Best Pract Res Clin Endocrinol Metab. 1999;13(3):451\u201360.","journal-title":"Baillieres Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"3820_CR2","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. Belgium J Clin Endocrinol Metab. 2006;91(12):4769\u201375.","journal-title":"Belgium J Clin Endocrinol Metab"},{"issue":"3","key":"3820_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377\u201382.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"3820_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13(2):220\u201340.","journal-title":"Endocr Rev"},{"issue":"11","key":"3820_CR5","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86(11):5256\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3820_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117(3):421\u20138.","journal-title":"J Neurooncol"},{"issue":"5","key":"3820_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000023180","volume":"49","author":"E Delgrange","year":"1998","unstructured":"Delgrange E, Crabb\u00e9 J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res Paediatr. 1998;49(5):250\u20133.","journal-title":"Horm Res Paediatr"},{"key":"3820_CR8","first-page":"78","volume":"2016","author":"E Sbardella","year":"2016","unstructured":"Sbardella E, Farah G, Fathelrahman A, Cudlip S, Ansorge O, Karavitaki N, et al. A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology. Endocrinol Diabetes Metab Case Rep. 2016;2016:78.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"3820_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/1097-0142(19850201)55:3<598::AID-CNCR2820550320>3.0.CO;2-S","volume":"55","author":"BW Scheithauer","year":"1985","unstructured":"Scheithauer BW, Randall RV, Laws ER, Kovacs KT, Horvath E, Whitaker MD. Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer. 1985;55(3):598\u2013604.","journal-title":"Cancer"},{"issue":"3","key":"3820_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000075375","volume":"61","author":"T Zornitzki","year":"2004","unstructured":"Zornitzki T, Knobler H, Nass D, Hadani M, Shimon I. Increased MIB-1\/Ki-67 Labeling index as a predictor of an aggressive course in a case of prolactinoma. Horm Res Paediatr. 2004;61(3):111\u20136.","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"3820_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1365-2265.1993.tb00351.x","volume":"38","author":"J Assies","year":"1993","unstructured":"Assies J, Verhoeff NPLG, Bosch DA, Hofland LJ. Intracranial dissemination of a macroprolactinoma. Clin Endocrinol (Oxf). 1993;38(5):539\u201346.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"3820_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/eje.1.02268","volume":"155","author":"M Kars","year":"2006","unstructured":"Kars M, Roelfsema F, Romijn JA, Pereira AM. Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol. 2006;155(4):523\u201334.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3820_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3171\/jns.1981.55.4.0615","volume":"55","author":"NA Martin","year":"1981","unstructured":"Martin NA, Hales M, Wilson CB. Cerebellar metastasis from a prolactinoma during treatment with bromocriptine: Case report. J Neurosurg. 1981;55(4):615\u20139.","journal-title":"J Neurosurg"},{"issue":"1","key":"3820_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1210\/jcem.85.1.6253","volume":"85","author":"P Petrossians","year":"2000","unstructured":"Petrossians P, De Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A, Beckers A. Malignant Prolactinoma Discovered by D2 Receptor Imaging. J Clin Endocrinol Metab. 2000;85(1):398\u2013401.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3820_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/jnnp.55.12.1205","volume":"55","author":"T Petterson","year":"1992","unstructured":"Petterson T, MacFarlane IA, MacKenzie JM, Shaw MD. Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychiatry. 1992;55(12):1205\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"3820_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","volume":"79","author":"PJ Pernicone","year":"1997","unstructured":"Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, et al. Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer. 1997;79(4):804\u201312.","journal-title":"Cancer"},{"issue":"1","key":"3820_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12022-009-9057-3","volume":"20","author":"MS Mallea-Gil","year":"2009","unstructured":"Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafa\u00f1e AMR, Ballarino C, Stalldecker G, et al. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocr Pathol. 2009;20(1):35\u201340.","journal-title":"Endocr Pathol"},{"key":"3820_CR18","first-page":"3","volume":"12","author":"D McCall","year":"2006","unstructured":"McCall D, Hunter SJ, Cooke RS, Herron B, Sheridan B, Atkinson AB. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clin Endocrinol (Oxf). 2006;12:3.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"3820_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/EJE-11-0656","volume":"166","author":"S Shimazu","year":"2012","unstructured":"Shimazu S, Shimatsu A, Yamada S, Inoshita N, Nagamura Y, Usui T, et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol. 2012;166(3):383\u201390.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3820_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11102-010-0237-4","volume":"13","author":"M Alberiche Ruano","year":"2010","unstructured":"Alberiche Ruano M, Boronat Cort\u00e9s M, Ojeda Pino A, Rodriguez Perez C, Grac\u00eda Nu\u00f1ez M, Marrero Arencibia D, et al. Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma. Pituitary. 2010;13(4):380\u20132.","journal-title":"Pituitary"},{"issue":"4","key":"3820_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s11102-009-0168-0","volume":"14","author":"LA Behan","year":"2011","unstructured":"Behan LA, Draman MS, Moran C, King T, Crowley RK, O\u2019Sullivan EP, et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary. 2011;14(4):362\u20136.","journal-title":"Pituitary"},{"issue":"2","key":"3820_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3820_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160(5):747\u201352.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"3820_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167(5):651\u201362.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"3820_CR25","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6390","key":"3820_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/bmj.287.6390.451","volume":"287","author":"HD Breidahl","year":"1983","unstructured":"Breidahl HD, Topliss DJ, Pike JW. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. BMJ. 1983;287(6390):451\u20132.","journal-title":"BMJ"},{"key":"3820_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF03350560","volume":"6","author":"D Dallabonzana","year":"1983","unstructured":"Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini PG. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest. 1983;6:47\u201350.","journal-title":"J Endocrinol Invest"},{"key":"3820_CR28","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1530\/eje.1.02353","volume":"156","author":"R Pivonello","year":"2007","unstructured":"Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SWJ, Hofland LJ. Novel insights in dopamine receptor physiology. Eur J Endocrinol. 2007;156:S13-21.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3820_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69(3):500\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3820_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000126764","volume":"60","author":"L Caccavelli","year":"1994","unstructured":"Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60(3):314\u201322.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"3820_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1210\/me.2013-1008","volume":"27","author":"D Radl","year":"2013","unstructured":"Radl D, De Mei C, Chen E, Lee H, Borrelli E. Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia. Mol Endocrinol Baltim Md. 2013;27(6):953\u201365.","journal-title":"Mol Endocrinol Baltim Md"},{"issue":"2","key":"3820_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1210\/endo-129-2-1101","volume":"129","author":"LA Kukstas","year":"1991","unstructured":"Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel JM, et al. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 1991;129(2):1101\u20133.","journal-title":"Endocrinology"},{"issue":"1","key":"3820_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11060-009-0107-y","volume":"99","author":"ZB Wu","year":"2010","unstructured":"Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, et al. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol. 2010;99(1):25\u201332.","journal-title":"J Neurooncol"},{"issue":"2","key":"3820_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/eje.1.02339","volume":"156","author":"A G\u00fcrlek","year":"2007","unstructured":"G\u00fcrlek A, Karavitaki N, Ansorge O, Wass JAH. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol. 2007;156(2):143\u201353.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"3820_CR35","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523\u2013631.","journal-title":"Physiol Rev"},{"issue":"2","key":"3820_CR36","doi-asserted-by":"publisher","first-page":"T101","DOI":"10.1530\/JOE-15-0213","volume":"226","author":"DR Grattan","year":"2015","unstructured":"Grattan DR. 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis. J Endocrinol. 2015;226(2):T101-122.","journal-title":"J Endocrinol"},{"issue":"1","key":"3820_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","volume":"101","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66\u201381.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"3820_CR38","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2002-020426","volume":"87","author":"MP Gillam","year":"2002","unstructured":"Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab. 2002;87(10):4447\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3820_CR39","first-page":"272","volume":"10","author":"C Missale","year":"1996","unstructured":"Missale C, Losa M, Sigala S, Balsari A, Giovanelli M, Spano PF. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol Baltim Md. 1996;10(3):272\u201385.","journal-title":"Mol Endocrinol Baltim Md"},{"issue":"17","key":"3820_CR40","doi-asserted-by":"publisher","first-page":"7961","DOI":"10.1073\/pnas.90.17.7961","volume":"90","author":"C Missale","year":"1993","unstructured":"Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci U S A. 1993;90(17):7961\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3820_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000065531","volume":"66","author":"R Lin","year":"2002","unstructured":"Lin R, Canfield V, Levenson R. Dominant negative mutants of filamin A block cell surface expression of the D2 dopamine receptor. Pharmacology. 2002;66(4):173\u201381.","journal-title":"Pharmacology"},{"issue":"3","key":"3820_CR42","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1210\/jc.2011-2902","volume":"97","author":"E Peverelli","year":"2012","unstructured":"Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S, et al. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab. 2012;97(3):967\u201377.","journal-title":"J Clin Endocrinol Metab"},{"key":"3820_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.brainresbull.2019.03.013","volume":"149","author":"B Hu","year":"2019","unstructured":"Hu B, Mao Z, Du Q, Jiang X, Wang Z, Xiao Z, et al. miR-93-5p targets Smad7 to regulate the transforming growth factor-\u03b21\/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma. Brain Res Bull. 2019;149:21\u201331.","journal-title":"Brain Res Bull"},{"issue":"9","key":"3820_CR44","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2169\/internalmedicine.40.857","volume":"40","author":"T Sabuncu","year":"2001","unstructured":"Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med Tokyo Jpn. 2001;40(9):857\u201361.","journal-title":"Intern Med Tokyo Jpn"},{"issue":"14","key":"3820_CR45","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"3820_CR46","first-page":"413","volume":"42","author":"K Eguchi","year":"1995","unstructured":"Eguchi K, Kawamoto K, Uozumi T, Ito A, Arita K, Kurisu K. Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. In Vitro Culture Studies Endocr J. 1995;42(3):413\u201320.","journal-title":"In Vitro Culture Studies. Endocr J."},{"issue":"7","key":"3820_CR47","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518\u201322.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3820_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf). 2000;53(1):53\u201360.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"3820_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM198201213060305","volume":"306","author":"IM Jackson","year":"1982","unstructured":"Jackson IM. Thyrotropin-releasing hormone. N Engl J Med. 1982;306(3):145\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"3820_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1227\/00006123-198903000-00020","volume":"24","author":"MJ Kupersmith","year":"1989","unstructured":"Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery. 1989;24(3):417\u201323.","journal-title":"Neurosurgery"},{"issue":"1\u20132","key":"3820_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000182496","volume":"38","author":"T Brue","year":"1992","unstructured":"Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res. 1992;38(1\u20132):84\u20139.","journal-title":"Horm Res"},{"issue":"10066","key":"3820_CR52","first-page":"29","volume":"108","author":"IE Laboy-Ortiz","year":"2016","unstructured":"Laboy-Ortiz IE, Velez-Maym\u00ed S, Hern\u00e1n Mart\u00ednez J, Trinidad R, Mangual M, Sanchez A, et al. Secondary resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man. Boletin Asoc Medica. 2016;108(10066):29\u201334.","journal-title":"Boletin Asoc Medica."},{"key":"3820_CR53","first-page":"48","volume":"4","author":"LI Astafeva","year":"2010","unstructured":"Astafeva LI, Kadashev BA, Trunin II. Rotin DL [Development of secondary resistance to dopamine agonists in a patient with giant prolactinoma]. Zh Vopr Neirokhir Im N N Burdenko. 2010;4:48\u201351.","journal-title":"Zh Vopr Neirokhir Im N N Burdenko"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03820-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03820-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03820-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:46:46Z","timestamp":1679863606000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03820-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3820"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03820-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Domain Specific Review Board of the National Healthcare Group has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}